相关实验视频
Updated: May 10, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
升的内甲素-1水平会通过PKC依赖的途径损害氧化的稳态
Danny Ramzy1, Vivek Rao, Laura C Tumiati
1Heart Transplant Program, University of Toronto, Toronto, Ontario, Canada.
Circulation
|July 6, 2006
概括
升高的内甲素-1 (ET-1) 通过通过蛋白激酶C (PKC) 信号来抑制内皮内甲氧化合成酶 (eNOS) 表达,从而损害氧化 (NO) 生产. ET-1 抗可能改善血管平衡.
科学领域:
- 心血管生物学 心血管生物学
- 内皮细胞功能 内皮细胞功能
- 分子信号传输的方法
背景情况:
- 内甲素-1 (ET-1) 对于血管度至关重要,并与缺血/反 (I/R) 损伤,血管和异体移植血管病变有关.
- 在I/R后ET-1水平升高可能会通过蛋白激酶C (PKC) 异形转位调节氧化 (NO) 生产.
研究的目的:
- 为了研究ET-1升高对人静脉内皮细胞 (HSVECs) NO产生的影响.
- 确定特定的PKC异型在调解ET-1对NO合成和eNOS表达的影响中的作用.
主要方法:
- 用ET-1或载体处理HSVEC,并通过酸盐/酸盐水平测量NO产量.
- 量化了eNOS,iNOS,caveolin-1和PKC异型的蛋白质表达.
- 在ET-1暴露和药理学调制后评估了PKC转位和活性.
主要成果:
- 在HSVEC中,ET-1暴露显著降低了NO的产生和eNOS蛋白的表达.
- 抑制PKC可以减少NO的产生和eNOS的表达,而PKC激活 (PMA) 可以增加它们.
- ET-1诱导了PKCdelta和PKCalpha的转位,抑制了PKClambda,并降低了整体PKC活性.
结论:
- 高水平的ET-1通过通过异构体特定的PKC机制抑制eNOS表达,损害了内皮NO的产生.
- 以博森坦为例的ET-1对抗作用促进了PKClambda转位,增强了PKC活性,并增加了NO的产生.
- 针对ET-1信号提供了一个潜在的治疗策略,以恢复血管平衡.
相关概念视频
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

